Rilpivirine: a step forward in tailored HIV treatment

Lancet. 2011 Jul 16;378(9787):201-3. doi: 10.1016/S0140-6736(11)60992-6.
No abstract available

Publication types

  • Comment

MeSH terms

  • Adenine / analogs & derivatives
  • Adenine / therapeutic use
  • Alkynes
  • Anti-HIV Agents / administration & dosage
  • Anti-HIV Agents / adverse effects
  • Anti-HIV Agents / therapeutic use*
  • Benzoxazines / therapeutic use
  • Clinical Trials, Phase III as Topic
  • Cyclopropanes
  • Delavirdine / therapeutic use
  • Deoxycytidine / analogs & derivatives
  • Deoxycytidine / therapeutic use
  • Drug Design
  • Drug Resistance, Viral / genetics
  • Emtricitabine
  • HIV Infections / drug therapy*
  • HIV Protease Inhibitors / therapeutic use
  • HIV-1 / drug effects*
  • HIV-1 / genetics
  • Humans
  • Multicenter Studies as Topic
  • Mutation
  • Nevirapine / therapeutic use
  • Nitriles / administration & dosage
  • Nitriles / adverse effects
  • Nitriles / therapeutic use*
  • Organophosphonates / therapeutic use
  • Pyrimidines / administration & dosage
  • Pyrimidines / adverse effects
  • Pyrimidines / therapeutic use*
  • Randomized Controlled Trials as Topic
  • Reverse Transcriptase Inhibitors / administration & dosage
  • Reverse Transcriptase Inhibitors / adverse effects
  • Reverse Transcriptase Inhibitors / therapeutic use*
  • Rilpivirine
  • Tenofovir
  • Viral Load / drug effects*

Substances

  • Alkynes
  • Anti-HIV Agents
  • Benzoxazines
  • Cyclopropanes
  • HIV Protease Inhibitors
  • Nitriles
  • Organophosphonates
  • Pyrimidines
  • Reverse Transcriptase Inhibitors
  • Deoxycytidine
  • Nevirapine
  • Tenofovir
  • Delavirdine
  • Rilpivirine
  • Emtricitabine
  • Adenine
  • efavirenz